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Abstract During tumor invasion, tumor epithelial cells
acquire migratory and invasive properties involving
important phenotypic alterations. Among these changes,
one can observe reorganization or a loss of cell–cell adhe-
sion complexes such as tight junctions (TJs). TJs are com-
posed of transmembrane proteins (occludin, claudins)
linked to the actin cytoskeleton through cytoplasmic adap-
tor molecules including those of the zonula occludens
family (ZO-1, -2, -3). We here evaluated the potential role
of ZO-2 in the acquisition of invasive properties by tumor
cells. In vivo, we showed a decrease of ZO-2 expression in
bronchopulmonary cancers, with a preferential localization
in the cytoplasm. In addition, in vitro, the localization of
ZO-2 varied according to invasive properties of tumor cells,
with a cytoplasmic localization correlating with invasion. In
addition, we demonstrated that ZO-2 inhibition increases
invasive and migrative capacities of invasive tumor cells.
This was associated with an increase of MT1-MMP. These
results suggest that ZO-2, besides its structural role in tight
junction assembly, can act also as a repressor of tumor
progression through its ability to reduce the expression of
tumor-promoting genes in invasive tumor cells.





DMEM Dulbecco’s modified eagle’s medium
ECM Extracellular matrix
EGF Epidermal growth factor
HBECs Human bronchial epithelial cells
MMP Matrix metalloproteinase
MT1-MMP Membrane-type 1 MMP
NES Nuclear exporting signal
NLS Nuclear localization signal
SAF-B Scaffold attachment factor-B
SSC Squamous cell carcinomas
TAZ Transcriptional coactivator with PDZ-
binding motif
TJ Tight junctions
YAP-2 Yes kinase-associated protein 2





In normal epithelia, tight junctions (TJs) are multi protein
complexes composed of transmembrane molecules
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(occludin, claudins and junctional adhesion molecules)
linked to the actin cytoskeleton through cytoplasmic sub-
membranous components. Among these cytoplasmic
components are the zonula occludens proteins (ZO-1, ZO-
2, ZO-3). ZO-1 is the oldest discovered ZO and is thus the
most well described but data are also accumulating on ZO-
2 while still little is known about ZO-3. ZO-2 binds
transmembrane molecules of TJs like occludin, and other
cytoplasmic molecules including ZO-1 but not ZO-3.
Besides its localization at the TJs, ZO-2 has also been
observed in other cell compartments. ZO-2 has indeed been
found to in the nuclei of sparse cultures, whereas in con-
fluent monolayers, ZO-2 is concentrated to at the TJs [1].
Accordingly, ZO-2 has been more recently shown to
interact with proteins that are not commonly associated to
TJ, such as nuclear matrix proteins [2]. Thus, in the
nucleus, ZO-2 has been described to colocalize with
splicing factor SC-35, with scaffold attachment factor-B
(SAF-B), and with transcription factors Jun and Fos, and
CCAAT/enhancer-binding protein (C/EBP) [1, 3, 4]. The
ability of ZO-2 to shuttle from the membrane to the cytosol
or nucleus relies on the presence of nuclear exporting
(NES) and nuclear localization (NLS) signals on its
sequence [1, 2, 5]. However, the functional consequences
of ZO-2 differential subcellular localization are still largely
unknown.
In normal epithelia, ZO-2 is expressed as two isoforms
ZO-2A and ZO-2C. ZO-2C protein is 23 amino acids
shorter at the N-terminus than ZO-2A [6, 7]. Three others
forms have also been described, two derived from form A
and one from form C. However little is known about the
potential functional differences between these isoforms. In
carcinomas, a reorganization of cell–cell junctions is fre-
quently observed. Accordingly, ZO-2 expression has been
shown to be altered in some carcinomas and a downregu-
lation of ZO-2 expression has been reported in lung car-
cinomas [8, 9]. However, in agreement with its ability to
shuttle to different cell compartments, other functions,
different to its structural role in TJs, have been described
for ZO-2 that could contribute to modulate tumor pro-
gression. As such, ZO-2 has more particularly been
implicated in the regulation of cell proliferation [10]. For
example, ZO-2 is able to suppress cell proliferation by
inhibiting expression of cyclin D1 (CD1) [11, 12].
Recently, Lechuga et al. have discovered a small protein
ZASP (ZO-2 Associated Speckle Protein), which interacts
with ZO-2. Overexpression of ZASP blocks the inhibitory
activity of ZO-2 on CD1 [13]. Also, in the nucleus, ZO-2
has been shown to bind YAP-2 (Yes kinase-associated
protein 2) that is an effector of the Hippo pathway. ZO-2
thus promotes the NLS and pro-apoptotic function of YAP-
2 through the activation of the Hippo pathway [14].
Through the contribution of ZO-2 to cancer progression is
unclear, it thus appears that it could modulate several
hallmarks of cancer progression.
Besides the reorganization or the loss of cell–cell
contacts, tumor invasion is also characterized by an
increased ability of tumor cells to degrade extracellular
matrix (ECM) components through an enhanced
expression of proteases including matrix metallopro-
teinases (MMPs). MMPs are a family of zinc endo-
peptidases that are either secreted or anchored to the
cell membrane. Among the membrane-type MMPs,
membrane-type 1 MMP (MT1-MMP) has been partic-
ularly implicated in pericellular proteolysis associated
with cell migration and invasion [15]. In numerous
studies, an overexpression of MT1-MMP has been
described in many types of human carcinomas [16]. In
addition, several data have reported that MT1-MMP is
produced by invasive tumor cells in vivo as well as
in vitro and so is associated with the acquisition of an
invasive phenotype by tumor cells [17]. Interestingly, a
correlation between the reorganization of tight junction
and the expression of MT1-MMP by epithelial tumor
cells has been established [18].
In the light of these data, we here aimed at evaluating
the potential role of ZO-2 in the acquisition of invasive
properties by tumor cells and in the regulation of MT1-
MMP. We showed an association between the cytoplasmic
localization of ZO-2 and the invasive phenotype of tumors
cells in bronchopulmonary carcinomas and in several
tumor cell lines. We also report that ZO-2 siRNA trans-
fection in invasive cells increases their invasive properties
and the expression of MT1-MMP.
Materials and methods
Tumor tissue samples
50 surgical specimens of bronchopulmonary carcinomas
obtained by lobectomy and/or pneumonectomy and 25
normal lung tissues matching to the tumor samples were
collected. These bronchopulmonary carcinomas included
29 squamous cell carcinomas (SSC) of stages I (7 cases), II
(12 cases) and III (10 cases) and 21 adenocarcinomas (AC)
of stages I (9 cases), II (6 cases) and III (6 cases) according
to the TNM classification.
Tumor cell lines
All human lung Calu-3, 16HBE, HBE4-E6/E7, BEAS-2B,
BZR cell lines used were obtained from the American Type
Culture Collection (Rockville, MD, USA). Human bron-
chial epithelial cells (HBECs) were isolated from human
normal bronchial tissues from patients undergoing surgery
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for bronchial carcinoma and were cultivated as described
previously [19]. Human lung cell lines Calu-3, 16HBE,
BEAS-2B, and BZR were grown in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco, Invitrogen, Carlsbad,
CA, USA) supplemented with 10 % fetal calf serum
(Gibco), and 100 UI/mL of penicillin and streptomycin
(Gibco), and HBE4-E6/E7 (HBE4) in keratinocyte serum
free medium (Gibco) supplemented with 0.2 ng/mL EGF
(epidermal growth factor) and 25 lg/mL BPE (Bovine
pituitary extract).
Reverse transcription-PCR analyses
RNA was extracted from normal and tumor lung tissues
frozen in liquid nitrogen with the RNA Easy Qiagen kit
(Qiagen, MD, USA) and from cells with the High Pure RNA
Isolation kit (Roche Diagnostics GmbH). RT-PCR was
performed with 10 ng of total RNA by using the GeneAmp
Thermostable rTth Reverse Transcriptase RNA PCR kit
(Applied Biosystem, Foster City, CA, USA) and pairs of
nucleotides. The reverse and forward primers (Eurogentec)
for ZO-2, ZO-2A, ZO-2C, MT1-MMP, GAPDH and 28S
were designed as follows : ZO-2 primers (forward 50-GCG
AGAAGCTGGTTTCAAGAGA-30, reverse 50-GCTTTCG





C-A-30), MT1-MMP primers (forward 50-GGATACCCAAT
GCCCATTGGCCA-30, reverse 50-CATTGGGCATCCA
GAAGAGAGC-30), GAPDH primers (forward 50-CCAGG
GCTGCTTTTAACTCTGGTA-30, reverse 50-GAGGGATC
TCGCTCCTGGAAGAT-30) and 28S primers (Forward
50-GTTCACCCAC TAATAGGGAACGTGA-30, Reverse
50-GGATTCTGACTTAGAGGCGTTCAGT-30). RT-PCR
analysis was done in the linear phase of amplification by
using a limited number of PCR cycles. RT-PCR products
were separated by acrylamide gel electrophoresis stained
with SYBR Gold (Molecular Probes) and quantified
by fluorimetric scanning (LAS-1000, Fuji, Stamford, CT,
USA). Data are expressed as mean ± SEM of 3 independent
in vitro experiments. A one-sample t test was done for in vitro
experiments and a p value \0.05 was considered significant.
A non-parametric test (Mann–Whitney U test) was per-
formed for RT-PCR analyses on lung cancer specimens and a
p value \0.05 was considered significant.
Immunohistochemistry
Immunohistochemistry was carried out on paraffin serial
sections. The sections were deparaffinized, rehydrated, and
treated with 3 % H2O2 for 20 min to quench endogenous
peroxidase activity. Slides were then incubated for over-
night at 4 C with a rabbit polyclonal antibody to ZO-2
(Sigma-Aldrich, St-Louis, MO, USA) or a mouse mono-
clonal antibody to MT1-MMP (clone 113-B7, Oncogene
Science, Cambridge, MA). After several washes, the slides
were successively incubated with biotin-coupled anti-rab-
bit/mouse antibody (Dako, Carpinteria, CA, USA) and then
with a horseradish peroxidase (HRP)-conjugated strepta-
vidin (Dako). The peroxidase activity was revealed using
AEC ? (Dako). The slides were briefly counterstained
with Mayer’s hematoxylin, mounted, and observed under a
Zeiss Axiophot microscope. Immunohistochemical detec-
tion of ZO-2 was scaled as follows: 0 = no detection,
1 = detection in \10 % of tumour cells, 2 = detection in
10–25 % of tumour cells, 3 = detection in 26–50 % of
tumour cells, 4 = detection in [50 % of tumour cells.
Negative controls were performed by omitting the primary
antibody or incubating with corresponding IgG isotype.
Digestive tissue, known to express ZO-2, was used as a
positive control.
Transfection of small interfering RNA
Three 19-nucleotide specific sequences were selected in the
coding sequence of ZO-2 (Gene ID: 9414) to generate
21-nucleotide sense and 21-nucleotide antisense strands of
the type (19 N) TT (N, any nucleotide). The sense and
antisense strands were then annealed to obtain duplexes with
identical 30 overhangs. The sequences were submitted to a
BLAST search against the human genome to ensure the
specificity of the siRNA to the targeted sequence. Three
corresponding scrambled duplexes, which do not recognize
any sequence in the human genome, were used as controls.
The 19-nucleotide specific sequences for the three ZO-2
siRNAs are as follows: ZO-2 Si1, 50-GGUGAACACACA
GGAUUUC-30; ZO-2 Si2, 50-GGAAACUCCACAGAG
CCUG-30; and ZO-2 Si3, 50-GCGGUUUGGGUCUCUG
AAG-30 (Eurogentec, Seraing, Belgium). For transfection of
the siRNA duplexes, 100,000 cells were plated in six-well
plates in 2 mL/well of culture medium. Twenty-four hours
after plating, the cells were transfected by phosphate calcium
precipitation by adding in each well 200 lL of a mixture
containing the a mix of three siRNA duplexes (20 nmol/L),
140 mmol/L NaCl, 0.75 mmol/L Na2HPO4, 6 mmol/L
glucose, 5 mmol/L KCl, 25 mmol/L HEPES, and
125 mmol/L CaCl2. Twenty-four hours after transfection,
the cells were extensively washed with phosphate buffered
saline (PBS) and incubated for 48 h in culture medium
before they were harvested for reverse transcription-PCR





Four micrograms of total RNA were labeled using the
GeneChip Expression 30 Amplification One-Cycle Target
Labeling kit (Affymetrix, Santa Clara, CA) following the
manufacturer’s protocol. The cRNA was hybridized to
Genechip Human Genome U133 Plus 2.0 Array (Affyme-
trix) according to the manifacturer’s protocol. Briefly,
double-stranded cDNA was synthesized from 4 lg of total
RNA primed with a poly-(dT)-T7 oligonucteotide. The
cDNA was used in an in vitro transcription reaction in the
presence of T7 RNA polymerase and biotin-labeled mod-
ified nucleotides during 16 h at 37 C. Biotinylated cRNA
was purified and then fragmented (35–200 nucleotides)
together with hybridization controls and hybridized to the
microarrays for 16 h at 45 C. Using Fluidics Station
(Affymetrix), the hybridized biotin-labeled cRNA was
revealed by successive reactions with streptavidin R-phy-
coerythrin conjugate, biotinylated anti-streptavidin anti-
body and streptavidin R-phycoerythrin conjugate. The
arrays were finally scanned with an affymetrix/Hewlett-
Packard GeneChip Scanner 3000 7G.
Western blotting analysis
Total protein extracts were made in RIPA buffer
(50 mmol/L Tris pH7.4, 150 mmol/L NaCl, 1 % (v/v) I-
gepal, Triton 1 %, 1 % (w/v) sodium deoxycholate, 0.1 %
(w/v) SDS, and 5 mmol/L iodoacetamid) supplemented
with complete protease inhibitor cocktail (Roche Diag-
nostics, Mannheim, Germany). Protein concentration was
determined with the detergent-compatible protein assay
(Bio-Rad). Ten microgram of total protein samples were
separated by electrophoresis on 10 % SDS–polyacrylamide
gels and then transferred on a polyvinylidene difluoride
membrane (NEN, Boston, MA, USA), which was then
blocked with 5 % milk (w/v), 0.1 % Tween 20 (v/v) in PBS
for 2 h. The membranes were then incubated overnight at
4 C with either a rabbit polyclonal antibody against ZO-2
(clone Z54.PL, Invitrogen) or mouse monoclonal antibody
to MT1-MMP (clone 2D7, provided by Dr Rio, IGBMC,
Illkirch, France). The filters were then incubated with
either a HRP-conjugated goat anti-rabbit or swine anti-
mouse secondary antibody (Dako). Signals were detected
using an Enhanced Chemiluminescence Plus kit (ECL?)
(Amersham Pharmacia Biotech, Buckinghamshire, United
Kingdom). Subsequent detection of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (clone 6C5, Chem-
icon, Millipore, Billerica, MA, USA) was performed on the
same filters as control. Data are expressed as mean ± SEM
of 3 independent experiments. A one-sample t test was
done and a p value \0.05 was considered significant.
Immunofluorescence
Confluent monolayers of cells cultured on glass coverslips
were fixed with methanol for 10 min at -20 C. The
coverslips were then satured for 30 min with 3 % BSA in
PBS, and incubated with a rabbit polyclonal antibody
against ZO-2 (clone Z54.PL, Invitrogen) for overnight at
4 C. After several washes, the coverslips were incubated
with an Alexa fluor 594-coupled anti-rabbit IgG (Molecular
Probes, Eugene, OR, USA) for 1 h. Nuclei were stained
with DAPI (Molecular Probes). The coverslips were then
mounted with aquapolymount antifading solution (Poly-
sciences Inc, Warrington, PA, USA) onto glass slides and
observed under a Zeiss fluorescence microscope.
Modified Boyden chamber invasion assay
The in vitro invasive properties of cells were assessed
using a modified Boyden chamber assay. A total of 105
cells were placed in the upper compartment of the invasion
chamber (BD BioCoat Matrigel Invasion Chamber; BD
Biosciences, Bedford, MA, USA). For MMP inhibition
experiments, GM6001 (20 lM) (Calbiochem, Merck Bio-
sciences, Darmstadt, Germany) was also added to the cells
in the upper compartment of the insert. The chambers were
incubated for 6 h (BZR) and 16 h (BEAS-2B) at 37 C.
The filters were then fixed in methanol for ten minutes and
stained with hematoxylin for 5 min. Quantification of the
invasion assay was done by counting the number of cells at
the lower surface of the filters (30 fields at 400-fold mag-
nification). Data are expressed as mean ± SEM of 3
independent experiments. A one-sample t test was done
and a p value \0.05 was considered significant.
Two dimensional migration assay
Two hours after seeding 1 9 105 cells/well into 12-well
plates, cell migration analysis was performed using an
inverted microscope (Axiovert 200, Zeiss, Oberkochen,
Germany) equipped with an environmental chamber
(Incubator XL-3, Pecon, Erbach, Germany) containing 5 %
CO2 in air at 37 C and a charge-coupled device camera
(Coolsnap, Roper Scientific, Photometrics, Tucson, AZ),
and driven by the Axiovision software (Zeiss). Image
sequences of the cells were recorded every 5 min for 5 h at
109 magnification and the trajectories and the migration
speeds were analyzed with the Manual tracking ImageJ
plugin (http://rsb.info.nih.gov/ij/plugins/track/track.html).
Data are expressed as mean ± SEM of 3 independent
experiments. A one-sample t test was done and a




ZO-2 delocalisation from the cell membrane correlates
with a low degree of tumor differentiation
In order to compare the expression of ZO-2 in vivo
between bronchopulmonary carcinomas and normal tis-
sues, we first carried out RT-PCR analyses to examine ZO-
2 mRNA expression. We found that ZO-2 is significantly
less expressed in carcinomas than in normal tissues
(Fig. 1A). Looking at the different ZO-2 mRNA isoforms,
we found that isoform ZO-2A is reduced in SCC and AC.
In contrast, ZO-2C mRNA expression was not altered in
carcinomas. Closer examination of a possible link between
ZO-2 modulation and tumor stage revealed no difference
between stages I, II and III of both SCC and AC for the
ZO-2 and its isoforms (Data not shown).
By immunohistochemistry, we showed that in the distant
normal bronchi, ZO-2 was localized at the apical cell
membrane of normal epithelial cells (Fig. 1B-a). In lung
parenchyma, ZO-2 was found at the cell membrane of type
II pneumocytes (Fig. 1B-d). In cancers, ZO-2 labeling was
heterogeneous in localization and intensity, and some
tumor clusters did not show any ZO-2 staining. In well
differentiated clusters of SCC and AC, ZO-2 was detected
at the cell membrane of tumor cells (Fig. 1B-b, e) whereas
in poorly differentiated clusters it was present in the
cytoplasm of tumor cells (Fig. 1B-c, f). Interestingly, in
AC, ZO-2 was rather detected at the basal pole of the
cancer cells towards the stroma or the basement membrane
(Fig. 1B-e, f). ZO-2 staining was also rarely observed in
the nucleus of some poorly differentiated tumor cells (data
not shown). In order to address this heterogeneity of ZO-2
localization in cancers, we established a scaling method to
evaluate, in each cancer specimen, the percentage of the
tumor area affected by a cytoplasmic, a membranous or a
nuclear staining of ZO-2 (Fig. 1B). Thus, for the majority
of lung cancers, most of the tumor compartment-associated
ZO-2 labeling is cytoplasmic. Only a small percentage of
the tumor area (\10 % of the tumor area) displays a
membranous ZO-2 staining. As for ZO-2 nuclear labeling,
it can only be observed in very restricted tumor areas and in
a very few number of cancers.
Our RT-PCR and immunohistochemistry results thus
showed that ZO-2 expression is reduced in bronchopulmo-
nary carcinomas and also that ZO-2 localization varied in
relationship with the dedifferentiation status of carcinomas.
The cytoplasmic localization of ZO-2 is correlated
with migratory/invasive capacities of cells
To further explore a potential relationship between ZO-2
expression and the invasive phenotype of tumor cells, we
compared the expression of ZO-2 in different human lung
cancer cell lines displaying various degrees of in vitro
invasiveness. The invasive phenotype of these lung cancer
cells, assessed by modified Boyden chamber assay, has
been extensively characterized previously in our laboratory
and was confirmed in the present study (Fig. 2A) [20].
Western blot analyses revealed that ZO-2 is expressed by
normal human bronchial epithelial cells and by all cell
lines (Fig. 2B). In addition, RT-PCR analyses showed that
the two ZO-2 isoforms (A and C) are also expressed by
normal human bronchial epithelial cells and by all cell
lines (Fig. 2C).
We next examined the subcellular localization of ZO-2
in normal human bronchial epithelial cells and in the dif-
ferent lung tumor cell lines by immunofluorescence
microscopy. Supporting our data obtained on the tumor
samples, ZO-2 was found at the cell membrane in normal
human bronchial epithelial cells and in non-invasive tumor
cell lines (as illustrated in HBEC and 16HBE cells in
Fig. 2D-a, b, respectively), whereas it displayed a pre-
dominantly diffuse cytoplasmic and nuclear staining in
invasive tumor cell lines (as illustrated in BZR cells in
Fig. 2D-c).
ZO-2 regulates invasiveness of lung tumor cells
To evaluate the potential role of ZO-2 in tumor cell inva-
sion, we used a RNA interference strategy to down-regu-
late the endogenous ZO-2 levels in two invasive tumor cell
lines (BEAS-2B and BZR). As shown in Fig. 3A, a pool of
three siRNA efficiently decreased ZO-2 protein levels. We
also observed a clear inhibition of the expression of the two
ZO-2 mRNA isoforms in the two cells lines treated with
this ZO-2 siRNA pool (Fig. 3B).
We then tested the effect of ZO-2 inhibition in lung
invasive tumor cells in two models of migration assays. In
the modified Boyden chamber assay, we observed a mod-
ification of invasive properties of tumor cells in vitro.
Indeed, ZO-2 inhibition increased the invasive potential of
BEAS-2B (2.25 ± 0.33 fold) (p \ 0.05) and BZR
(1.54 ± 0.06 fold) (p \ 0.05) cells (Fig. 3C). In the 2D
migration assay, trajectories of BEAS-2B and BZR trans-
fected with ZO-2 siRNA are longer and their migration
speed was significantly increased when compared to con-
trol cells (24.73 ± 0.12 versus 13.47 ± 0.12 lm/h and
32.87 ± 0.82 versus 24.09 ± 0.0.73 lm/h, respectively)
(p \ 0.05) (Fig. 3D).
We also explored the effect of ZO-2 siRNA treatment on
cell proliferation. ZO-2 inhibition had no effect on cell
proliferation of lung cell lines in the first 48 h (data not
shown), minimizing a potential impact of modulations of
cell proliferation on the results obtained in both Boyden
chamber and the 2D cell migration assays.
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ZO-2 regulates MT1-MMP expression in lung invasive
tumor cells
As the inhibition of ZO-2 expression modulated the inva-
sive properties of lung tumor cells, we aimed at identifying
by larrays molecular factors implicated in this process that
could be targeted by ZO-2 silencing. We used GeneChips
Affymetrix (AffymetrixTM) to screen and compare the
mRNA expression profile in invasive lung tumor BZR cells
transfected with a ZO-2 siRNA and a corresponding
Fig. 1 ZO-2 expression in normal tissues and bronchopulmonary
carcinomas. A RT-PCR analyses of ZO-2, ZO-2A and ZO-2C
expression in both adenocarcinomas (AC) and squamous cell
carcinomas (SCC) and normal tissue counterpart, normal bronchi
(NB) and normal lung (NL), respectively. ZO-2 values have been
normalized to the values obtained for 28S. Data are expressed as
scatter graphs comparing the median of each group of tissues
(**p \ 0.01; ***p \ 0.001). B ZO-2 immunostaining performed on
normal bronchi and lung parenchyma (a, d), on well differentiated
adenocarcinomas and squamous cell carcinomas (b, e) and on poor
differentiated adenocarcinomas and squamous cell carcinomas (c,
f) (bars 120 lm). A scaling analysis is shown, which reports the
percentage of tumor area displaying membrane-associated (Memb.),
cytoplasmic (Cyto.) or nuclear (Nucl.) ZO-2 staining
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scrambled control siRNA. Among the modulated genes,
MT1-MMP was strongly up-regulated following ZO-2
inhibition (Table 1; Fig. 4). This is of particular interest
given the implication of MT1-MMP in invasive processes.
We first confirmed the larray results by RT-PCR and
Western blotting. We observed that BEAS-2B and BZR
cells transfected with ZO-2 siRNA indeed expressed more
MT1-MMP mRNA (1.68 ± 0.08 and 1.63 ± 0.13 fold
respectively) (p \ 0.05 and p \ 0.01 respectively) than
their respective controls (Fig. 4A). Similarly, western
blotting also revealed a significant augmentation of the
63 kDa active form of MT1-MMP (Fig. 4B). Indeed,
BEAS-2B and BZR cells transfected with ZO-2 siRNA
expressed more MT1-MMP proteins than their respective
controls (2.58 ± 0.56 and 2.48 ± 0.27 fold, respectively;
p \ 0.05 and p \ 0.01, respectively). Moreover, treatment
of BEAS-2B and BZR cell lines with broad-spectrum
synthetic MMP inhibitor GM6001 abolished siRNA ZO-2-
increased invasion, confirming that the pro-invasive effect
of ZO-2 depletion is related to MMP activity (p \ 0.001)
(Fig. 4C).
In addition, strengthening our in vitro observations, RT-
PCR analyses on bronchopulmonary carcinomas and nor-
mal tissues established an inverse relationship between
ZO-2 and MT1-MMP. Thus, ZO-2 was found significantly
less expressed in carcinomas than in normal tissues
whereas MT1-MMP was significantly more expressed in
carcinomas than in normal tissues (Fig. 4D). Also, the
immunodetection of MT1-MMP and ZO-2 on serial lung
tumor sections allowed to observe that MT1-MMP was
preferentially expressed in ZO-2-negative tumor areas
(Fig. 4E). While in all cases ZO-2 negative tumor areas
expressed MT1-MMP, not all MT1-MMP positive areas
lacked ZO-2 staining.
Discussion
In this study, we showed a decrease of ZO-2 expression in
SCC and AC as compared to normal tissues and observed a
heterogenous cytoplasmic localization of ZO-2 in poorly
differentiated bronchopulmonary carcinomas. In addition,
in vitro, we demonstrated that the localization of ZO-2
varies according to invasive/migratory properties of tumor
cells. Interestingly, we further demonstrated that ZO-2
inhibition increases invasive capacities of tumor cells in
association with enhanced expression of MT1-MMP.
First, we observed that mRNA levels of ZO-2 are
reduced in human bronchopulmonary carcinomas as com-
pared to normal lung tissues. In agreement with our find-
ings, previous data have reported a decrease of ZO-2 in
tumor tissues of breast and lung when compared to normal
tissue [8, 9]. These data are in agreement with the notion
that the expression of tight junction proteins is down
Fig. 2 Expression and localization of ZO-2 in human lung cancer
cell lines displaying various degrees of in vitro invasiveness.
A Analysis of the invasive capacities of human lung cell lines in a
modified Boyden chamber assay. B Western blot analyses of ZO-2
and GAPDH expression in human bronchial epithelial cells (HBECs)
and lung cancer cell lines. C RT-PCR analyses of ZO-2 and its
isoforms expression in HBECs and in lung cancer cell lines.
D Localization of ZO-2 in HBECs (a), in non-invasive (b) and in
invasive (c) tumor cell lines (16HBE and BZR, respectively)
(bar = 40 lm)
Clin Exp Metastasis
123
regulated in carcinomas [21]. Complementing these
observations, we have shown a significant decrease of the
ZO-2A isoform in lung tumors, while the ZO-2C isoform
showed no difference as compared to normal tissue. The
literature regarding the two described ZO-2 isoforms is
extremely scarce and reports that the expression of specific
ZO-2 isoforms is dependent on the cell type suggest dif-
ferent biological functions for these two molecules [7]. In
agreement with our observations, Chlenski et al. [6] have
not detected isoform A in pancreatic adenocarcinoma when
compared to normal tissues, while isoform C was detected
in all tumor samples. Thus, our results suggest that a
diminution of the ZO-2A form could be specifically
involved in the process of tumor progression of broncho-
pulmonary carcinomas.
In addition to a decrease of ZO-2 expression in bron-
chopulmonary carcinomas, our results showed a different
subcellular localization of this molecule in tumor cells as
compared to normal lung epithelial cells. Indeed, ZO-2 is
localized at the apical cell membrane of normal lung epi-
thelial cells and in the cytoplasm and/or nucleus of poorly
differentiated tumor cells. Similarly, Martin et al. [22] have
reported that ZO-2 displayed a cytoplasmic staining in
infiltrating tumor cells of breast cancer, whereas it was
found at the cell membrane of normal mammary gland
epithelial cells. Moreover, we also observed that in well
differentiated tumors clusters of SCC and AC, ZO-2 was
detected at the cell membrane of the tumor cells, whereas
in poorly differentiated tumor clusters, it was present in the
cytoplasm of the tumor cells. Taken together, these data
suggest that ZO-2 relocalization from the cell membrane to
the cytoplasm/nucleus is associated with the dedifferenti-
ation status of carcinomas. Emphasizing these in vivo data,
our in vitro data shows an association between a cyto-
plasmic localization of ZO-2 and high migratory/invasive
capacities of tumor cell lines. Indeed, ZO-2 is present at the
Fig. 3 Effect of ZO-2 siRNA on in vitro cell invasion of invasive
lung tumor cells. A Western blot analyses of ZO-2 and GAPDH
expression on total extracts of BEAS-2B and BZR cells transfected
ZO-2 siRNA (ZO-2 si) or scrambled siRNA (ZO-2 scr). B RT-PCR
analyses of ZO-2, ZO-2 isoforms (ZO-2A and ZO-2C) and GAPDH
expression in BEAS-2B and BZR cells transfected with ZO-2 siRNA
(ZO-2 si) or scrambled siRNA (ZO-2 scr). C Boyden chamber
analyses of invasive properties of ZO-2 siRNA (ZO-2 si) -transfected
cells compared to scrambled control siRNA (ZO-2 scr)-transfectants
(*p \ 0.05). D Phase-contrast photographs and trajectories of BEAS-
2B transfected with scrambled (ZO-2 scr) or ZO-2 siRNA (ZO-2 si) in
a two-dimensional migration assay (bars 120 lm). Comparison of
migration speeds of BEAS-2B and BZR transfected with scrambled
(ZO-2 scr) or ZO-2 siRNA (ZO-2 si) (***p \ 0.001)
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cell membrane of normal bronchial epithelial cells and of
lung non-invasive cells and is located in the cytoplasm and/
or nucleus of lung invasive cell lines. Previously, Islas
et al. [1] have demonstrated that ZO-2 was found at the
membrane in MDCK confluent cell monolayers, while it
was present in the nucleus in sparse cells. Taken together,
these data support the general concept that ZO-2 relocal-
ization from the membrane to the cytoplasm/nucleus could
be associated with dedifferentiation and increased migra-
tion/invasive properties of epithelial tumor cells.
Interestingly, we observed an upregulation of the pro-
invasive gene MT1-MMP in response to ZO-2 siRNA
transfection in invasive tumor cell lines. Moreover, we also
showed that ZO-2 inhibition induces an increase of inva-
sive capacities of these cell lines. All the data suggest that
cytoplasmic and/or nuclear ZO-2, even though associated
with dedifferentiation and invasive status of tumor cells,
could remain a negative regulator of invasive processes.
These latest observations suggest different function
between ZO-1 and ZO-2. Indeed, we and others have
shown an association between a cytoplasmic/NLS of ZO-1
and an invasive/migratory behavior of different cell lines
[18, 23, 24]. However, in contrast with our observations on
ZO-2, decreasing ZO-1 by RNA interference in invasive
cell lines was shown to decrease both MT1-MMP expres-
sion and invasive properties [18]. In the same line of
thinking, Reichert et al. reported a stimulation of EMT
when overexpressing a truncated form of ZO-1 that is less
prone to associate to TJs [25]. This EMT promoting effect
has been associated with an activation of the beta catenin
pathway. The actual belief regarding ZO-1 is thus that
cytoplasmic/nuclear pools of ZO-1 would rather have an
oncogenic activity. This is thus contrasting with our current
findings on ZO-2, suggesting an anti-tumoral role of ZO-2
independently of its subcellular localization.
The mechanisms by which ZO-2 may regulate tumor
invasion remain to be determined. A first hypothesis would
be that ZO-2 could act directly as a repressor of pro-invasive
transcription factors. Indeed, previous studies have shown
that ZO-2 is able to colocalize with several proteins binding
nucleic acids such as SC-35 factor, SAF-B factor, and to
associate with the transcription factors Fos, Jun and CCAAT/
enhancer binding protein [1, 3, 4]. In addition, recent work
showed that ZO-2 negatively regulates the transcriptional
function of TAZ (Transcriptional coactivator with PDZ-
binding motif), a factor implicated in the promotion of epi-
thelial-mesenchymal transition and tumor progression [26–
28]. Another mean by which ZO-2 could regulate tumor
invasion is by modifying the shuttling between different
subcellular compartments of factors regulating tumor inva-
sion-modulating genes. For example, the involvement of
ZO-2 in modulating the Hippo tumor suppressor pathway
through its interaction with YAP-2 (Yes kinase-associated
protein-2) has recently been uncovered. Association of YAP-
2 with ZO-2 allows its localization to the nucleus and thus
increases its pro-apoptotic function [14, 29]. In addition to
YAP-2, ZO-2 can also serve as a shuttle to deliver ARVCF
into the nucleus [14, 30]. Thus, the absence or the diminution
of ZO-2 expression, as we mimicked by siRNA transfection,
could have a significant impact on the different functions of
these factors. In this context, ZO-2 could be involved in
different signaling activities modulating invasion-associated
target genes.
Table 1 Analysis by GeneChips Affymetrix of mRNA profiles in
BZR cells transfected with siRNA against ZO-2 compared with
corresponding scrambled siRNA
Genes siZO-2/scrZO-2 Genes siZO-2/scrZO-2
CTSF 5.98 ETV6 0.49
MYB 5.97 UBE2H 0.49
IRF7 4.1 IL1B 0.49
CDKL3 3.86 MGST1 0.49
FOSB 3.55 STAT5B 0.49
CASP3 3.49 HMGB1 0.48
CTSH 3.47 FOXP1 0.47
RRM2 3.17 NQO1 0.46
TLE2 3.08 SMAD2 0.45
ADAM9 2.94 NOTCH2 0.45
TP53 2.94 ITGA10 0.44
ZEB2 2.83 STAT3 0.44
MCM7 2.83 CASP6 0.43
CCNE2 2.56 TJP2 (2) 0.43
CDKN2C 2.5 PPIC 0.43
HMGB2 2.45 PSME3 0.43
CCNE1 2.45 UBE2J2 0.42
MT1-MMP 2.43 E2F5 0.41
CCNY 2.37 MYBL1 0.40
TIMP2 2.33 KRT7 0.39
DVL1 2.32 MAPK9 0.39
CDCA1 2.30 CDK6 0.38
E2F2 2.30 TNFSF10 0.37
PKMYT1 2.29 IGF2BP3 0.36
TK1 2.27 ARRB1 0.36
TGFB1/1 2.22 TNFSF14 0.33
MAP4K3 2.22 NOTCH1 0.33
UBE2Z 2.22 ITGB7 0.32
ETV4 2.18 PECAM1 0.27
MAP2K7 2.10 RHOB 0.26
CDK10 2.03 PPID 0.26
MDM1 2.03 LDHA 0.25
CCNG2 2.02 TJP2 (1) 0.20
PSMB9 2.01 KRT81 0.15
PSME3 0.50 IL1A 0.11
HMGN4 0.49 CAPN6 0.04
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In conclusion, our data show that ZO-2, even when not
associated with adhesion complexes, can negatively mod-
ulate tumor invasion through its ability to downregulate the
expression of pro-invasive genes such as MT1-MMP.
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